VIDEO: EGFR antibody recommended for first-line treatment of certain colorectal cancers
Click Here to Manage Email Alerts
In this video, Smitha S. Krishnamurthi, MD, discussed the results of the STRATEGIC-1 trial, which she said validates a common initial treatment strategy for patients with RAS and BRAF wild-type metastatic colorectal cancer.
The phase 3 randomized trial presented at ASCO Annual Meeting compared two strategies for treatment including first-line FOLFIRI-cetuximab followed by second-line mFOLFOX6-bevacizumab compared with a three-line treatment starting with mFOLFOX6-bevacizumab followed by second-line FOLFIRI-bevacizumab and an EGFR antibody in the third line.
"I certainly will recommend EGFR antibody first line because of this, but some patients may opt to use it in a later line; we know that many of our patients are weary of the rash that EGFR antibody causes, so it may not be for everybody," Krishnamurthi, a gastrointestinal medical oncologist at Cleveland Clinic said.
Collapse
Read more about
Click Here to Manage Email Alerts